[
    {
        "other_ids": [
            {
                "name": "Study Protocol Other Identifier",
                "value": "2017-004034-29"
            },
            {
                "name": "Study Protocol Other Identifier",
                "value": "CAAA602A12101"
            }
        ],
        "amendment_date": null,
        "keywords": [
            "Genital Neoplasms",
            "Male",
            "Urogenital Neoplasms",
            "Neoplasms by Site",
            "Neoplasms",
            "Prostatic Diseases",
            "Cancer of Prostate",
            "Cancer of the Prostate",
            "Neoplasms",
            "Prostate",
            "Neoplasms",
            "Prostatic",
            "Prostate Cancer",
            "Prostate Neoplasms",
            "Prostatic Cancer",
            "Prostate-Specific Membrane Antigen",
            "PSMA",
            "PSMA radioligand therapy"
        ],
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Advanced Accelerator Applications",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Male patients, 18 years of age or older"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Signed and dated written ICF by the patient or legally acceptable representative prior to any study-specific procedures"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Histologically confirmed adenocarcinoma of the prostate"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Serum testosterone levels < 50 ng/dL after surgical or continued chemical castration"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Metastatic disease documented by CT/MRI or bone scan (not older than 28 days at enrollment) revealing at least one metastatic lymph-node, visceral metastasis and/or bone metastasis"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Positive 68Ga-PSMA-R2 PET/CT scan for central eligibility assessment. Patients who receive 68Ga-PSMA-R2 as part of separate clinical protocol are eligible (must meet all study eligibility criteria)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Documented progressive mCRPC on or after the last systemic treatment administered for the advanced disease including metastatic disease. Disease progression defined as increasing serum PSA (per PCWG3), radiological progression or \u2265 2 new bone lesions."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Must have received prior systemic treatment for mCRPC including CYP17 inhibitors and/or androgen-pathway inhibitors (i.e. abiraterone and/or enzalutamide when available) and one and no more than one line of chemotherapy for the advanced disease (unless ineligible (unfit) to receive chemotherapy)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "At least 28 days elapsed between last anti-cancer treatment administration and the initiation of study treatment (except for Luteinizing Hormone-releasing Hormone [LHRH] or Gonadotropin-releasing Hormone [GnRH]), or resolution of all previous treatment related toxicities to CTCAE version 5.0 grade of \u2264 1 (except for chemotherapy induced alopecia and grade 2 peripheral neuropathy or grade 2 urinary frequency which are allowed). Prior major surgery must be at least 12 weeks prior to study entry."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Eastern cooperative oncology group (ECOG) performance status of 0-2 with a life expectancy \u2265 6 months"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at baseline"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Platelet count of >100 x10e9/L"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "White blood cell (WBC) count > 3,000/mL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Neutrophil count > 1,500/mL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Hemoglobin \u2265 10 g/dL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Serum creatinine < 1.5 x upper limit normal (ULN) or estimated glomerular filtration rate (GFR) > 50 mL/min based upon Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Patients with estimated GFR between 50 - 60 mL/min at baseline will require a 99mTc-DTPA GFR test and only patients with non-obstructive pathology will be included in the study."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 16,
                    "description": "Total bilirubin < 3 x ULN (except if confirmed history of Gilbert's disease)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 17,
                    "description": "Baseline serum albumin > 30 g/L"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 18,
                    "description": "Aspartate aminotransferase (AST) < 3 times the ULN"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 19,
                    "description": "For male patients with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 6 months from receiving the last dose of IP"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any other histology different than adenocarcinoma."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Diffuse bone-marrow involvement (i.e. \"superscan\" defined as bone scintigraphy in which there is excessive skeletal radioisotope uptake [>20 bone lesions] in relation to soft tissues along with absent or faint activity in the genitourinary tract due to diffuse bone/ bone marrow metastases)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Prior exposure to radioligand therapy radioisotope therapy (e.g. 89Sr), systemic radiotherapy or 223Ra-therapy."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, any level of urinary obstruction requiring indwelling/condom catheters"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "Spinal cord compression or brain metastases"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "Uncontrolled pain that results in patient's lack of compliance with the imaging procedures"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "Uncontrolled cardiovascular history, defined as:"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 27,
                    "description": "Congestive heart failure (New York Heart Association [NYHA] II, III, IV)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 28,
                    "description": "Mean resting corrected QT interval (QTc) >450 millisecond (msec), obtained from 3 ECGs recordings, using the screening clinic ECG machine-derived QTc value."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 29,
                    "description": "Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250 msec)."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 30,
                    "description": "Any factor increasing the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 31,
                    "description": "Other known co-existing malignancies except non-melanoma skin cancer or low grade superficial bladder cancer unless definitively treated and proven no evidence of recurrence for 5 years."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 32,
                    "description": "History of deep vein thrombosis and/or pulmonary embolism within 4 weeks of enrollment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 33,
                    "description": "Known incompatibility to CT or PET scans."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 34,
                    "description": "Any evidence of severe or uncontrolled systemic or psychiatric diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 35,
                    "description": "Active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 36,
                    "description": "Patients who have received any investigational treatment agent within the last 28 days."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 37,
                    "description": "Known allergies, hypersensitivity, or intolerance to the IP or its excipients"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 38,
                    "description": "Known history of myelodysplastic syndrome/leukemia at any time"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 39,
                    "description": "Patient is unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator that the patient is not suitable for participation in the study."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "MALE",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ACTUAL",
        "detail_description": "Recruitment for PROter A206T-G01-001 (NCT03490838) was halted in Phase I by sponsor decision.\r\n      Phase II expansion portion of the study was never initiated. Importantly, this recruitment\r\n      halt was not a consequence of any safety concern. Ongoing patients at the time of recruitment\r\n      halt continued per protocol and completed the 1 year safety follow-up prior to early study\r\n      termination.\r\n\r\n      The primary objective of the Phase I portion of the study to assess the safety and\r\n      tolerability of 177Lu-PSMA-R2 and to assess Dose Limiting Toxicities (DLTs) and determine the\r\n      maximum tolerated dose (MTD) (if reached) and the recommended Phase II dose was not reached\r\n      due to early recruitment halt.",
        "official_title": "A Phase 1/2 Open-label, Multi-center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients With Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-resistant Prostate Cancer, Following Previous Systemic Treatment",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Days 1 through 8 post-treatment",
                "name": "Phase I: 177Lu-PSMA-R2 plasma concentration",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Prior to dosing on Day 1 and every 12 weeks until 1 year after disease progression or early study termination whichever comes first",
                "name": "Phase I and II: Brief Pain Inventory-short Form (PBI-SF)",
                "description": "The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase I and II: Duration of Response (DoR)",
                "description": "Duration of Response (DoR) according to RECIST v1.1 is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From date of randomization assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase I and II: Objective Response Rate (ORR)",
                "description": "ORR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) per RECIST 1.1.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Prior to dosing on Day 1 and every 12 weeks until 1 year after disease progression or early study termination whichever comes first",
                "name": "Phase I and II: Patient Reported Outcomes (PRO) of Eye Dryness using Xerophthalmia Questionnaire",
                "description": "The Xerophthalmia questionnaire is a questionnaire used to describe eye dryness and its effects on daily life. It consists of 3 questions. The first 2 questions scores range from 1 (\"never\") to 4 (\"constantly\") and the last question is a Yes/No question about previous dry eye diagnosis. The sum of the scores of the first 2 questions produces a total score (score range from 2-8). A low score corresponds to a good quality of life while a high score means a poor quality of life due to the dry eye.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Prior to dosing on Day 1 and every 12 weeks until 1 year after disease progression or early study termination whichever comes first",
                "name": "Phase I and II: Patient Reported Outcomes (PRO) of Mouth Dryness using Xerostomia Questionnaire",
                "description": "The Xerostomia questionnaire is a questionnaire used to describe mouth dryness and its effects on daily life. It consists of 8 questions with each question score ranging from 0 (\"never\"/\"none\") to 10 (\"worst\"). The sum of the 8 scores produces a total score (score range from 0-80). A low score corresponds to a good quality of life while a high score means a poor quality of life due to the dry mouth.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Week 13 (12 weeks after the first 177Lu-PSMA-R2 injection)",
                "name": "Phase I and II: Prostate-Specific Antigen (PSA) response rate 30",
                "description": "PSA response rate 30 is defined as the proportion of participants who have a greater or equal 30% in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later, as per Prostate Cancer Working Group 3 (PCWG3) criteria.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From randomization till 30 days safety follow-up, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase I and II: Treatment Emergent Adverse Event (TEAE) rate",
                "description": "The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 (before the start of infusion, at the mid-point, and just before the end of infusion, then at post infusion at approximately 5, 15, 30 minutes, 1, 2, 4, 6, 8, 24, 40 (+/- 4 hours), 48 hours), Day 4 (+2 days) and Day 8 post end of infusion",
                "name": "Phase I: Area under the plasma concentration-time curve (AUC) of 177Lu-PSMA-R2",
                "description": "Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC will be listed and summarized using descriptive statistics.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Days 1 through 8 post-treatment",
                "name": "Phase I: Dosimetry",
                "description": "Radiation (Gy, Gy/MBq) update by critical organs and metastatic lesions",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Prior to dosing on Day 1 and every 12 weeks until 1 year after disease progression or early study termination whichever comes first",
                "name": "Phase II: Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Module (EORTC QLQ-PR25) Score",
                "description": "The EORTC QLQ-PR25 is a prostate cancer module for the assessment of health-related quality of life (HRQoL). It consists of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Questions use a 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Prior to dosing on Day 1 and every 12 weeks until 1 year after disease progression or early study termination whichever comes first",
                "name": "Phase II: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score",
                "description": "The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4 point scales ranging from \"Not at all\" to \"Very much.\" The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from \"Very poor\" to \"Excellent.\" For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From date of randomization till 30 days safety fup, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase II: Disease Control Rate (DCR)",
                "description": "DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST 1.1.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 8 weeks after the first 177Lu-PSMA-R2 dose",
                "name": "Phase I: Incidence of dose limiting toxicities (DLTs) during first cycle of study treatment.",
                "description": "A dose-limiting toxicity (DLT) is defined as any toxicity not attributable to the disease or disease-related processes under investigation, the time window for DLT assessment period is Cycle 1. To be considered a DLT, it must be related to the IP (attributions: possible, probable, and definite) while fulfilling one of the following criteria as per the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From date of randomization until date of death from any cause, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase II: Overall Survival (OS)",
                "description": "OS is defined as the time to death for any cause.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Week 13 (12 weeks after the first 177Lu-PSMA-R2 injection)",
                "name": "Phase II: Prostate-Specific Antigen (PSA) response rate 50",
                "description": "PSA response rate 50 is defined as the proportion of participants who have a greater or equal 50% in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later, as per Prostate Cancer Working Group 3 (PCWG3) criteria.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase II: Radiographic Progression Free Survival (rPFS)",
                "description": "rPFS is defined as the time to radiographic progression by PCWG3-modified RECIST v1.1 or death.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From date of randomization until date of death from any cause, assessed up to 4 years (estimated final OS analysis)",
                "name": "Phase II: Time to Prostate Specific Antigen (PSA) progression",
                "description": "PSA progression is defined as the time from the date of first dose of 177Lu-PSMA-R2 injection to the first date that a >= 25% increase in PSA and an absolute increase of 2 ng/mL or more from the nadir was documented and confirmed by a second consecutive value obtained 3 or more weeks later.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 (before the start of infusion, at the mid-point, and just before the end of infusion, then at post infusion at approximately 5, 15, 30 minutes, 1, 2, 4, 6, 8, 24, 40 (+/- 4 hours), 48 hours), Day 4 (+2 days) and Day 8 post end of infusion",
                "name": "Phase I: Maximum plasma concentration (Cmax) of 177Lu-PSMA-R2",
                "description": "Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Day 1 (before the start of infusion, at the mid-point, and just before the end of infusion, then at post infusion at approximately 5, 15, 30 minutes, 1, 2, 4, 6, 8, 24, 40 (+/- 4 hours), 48 hours), Day 4 (+2 days) and Day 8 post end of infusion",
                "name": "Phase I: Minimum plasma concentration (Cmin) of 177Lu-PSMA-R2",
                "description": "Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmin will be listed and summarized using descriptive statistics.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Week 13 (12 weeks after the first 177Lu-PSMA-R2 injection)",
                "name": "Phase I: Prostate-Specific Antigen (PSA) response rate 50",
                "description": "PSA response rate 50 is defined as the proportion of participants who have a greater or equal 50% in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later, as per Prostate Cancer Working Group 3 (PCWG3) criteria.",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 6,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03490838",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Lab Value",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "Testosterone Less than 50 Nanograms per Deciliter",
                    "Testosterone Less than 50 Nanograms/Deciliter"
                ],
                "nci_thesaurus_concept_id": "C157378",
                "name": "Testosterone Less than 50 ng/dL",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C157377",
                    "C77140",
                    "C3367",
                    "C36292"
                ],
                "parents": [
                    "C157377"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Protease Gene",
                    "Proteinase Gene"
                ],
                "nci_thesaurus_concept_id": "C26003",
                "name": "Peptidase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25804",
                    "C16612",
                    "C21281"
                ],
                "parents": [
                    "C25804"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Hydrolase Family Gene"
                ],
                "nci_thesaurus_concept_id": "C25804",
                "name": "Hydrolase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C21281",
                    "C16612"
                ],
                "parents": [
                    "C21281"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "KLK3",
                    "Kallikrein 3, (Prostate Specific Antigen) Gene",
                    "PSA"
                ],
                "nci_thesaurus_concept_id": "C26585",
                "name": "KLK3 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C25804",
                    "C16612",
                    "C21281",
                    "C26003"
                ],
                "parents": [
                    "C26003"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C138961",
                "name": "PSA Level Finding",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C21281",
                    "C36292",
                    "C16612",
                    "C26585",
                    "C77140",
                    "C3367",
                    "C25804",
                    "C26003"
                ],
                "parents": [
                    "C26585",
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C129259",
                "name": "Castration Levels of Testosterone",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140",
                    "C157377"
                ],
                "parents": [
                    "C157377"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C157377",
                "name": "Testosterone Level Finding",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21281",
                "name": "Enzyme Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "Elevated PSA",
                    "Elevated Prostate Specific Antigen",
                    "Increasing PSA",
                    "PSA Elevated",
                    "Prostate Specific Antigen Progression",
                    "Rising PSA"
                ],
                "nci_thesaurus_concept_id": "C123611",
                "name": "PSA Progression",
                "semantic_types": [
                    "Finding",
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C138961",
                    "C3367",
                    "C77140",
                    "C21281",
                    "C16612",
                    "C26003",
                    "C25804",
                    "C26585",
                    "C36292"
                ],
                "parents": [
                    "C138961",
                    "C26585"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": null,
        "current_trial_status_date": "2022-06-02",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "CRPC",
                    "Castration-Resistant Prostate Carcinoma",
                    "Metastatic Castration-Resistant Prostate Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C130234",
                "name": "Castration-Resistant Prostate Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C167255",
                    "C8946"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IV Prostate Carcinoma AJCC v8",
                    "Stage IV Prostate Cancer AJCC v8"
                ],
                "nci_thesaurus_concept_id": "C140173",
                "name": "Stage IV Prostate Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C140163"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IVA Prostate Carcinoma AJCC v8",
                    "Stage IVA Prostate Cancer AJCC v8",
                    "IVA"
                ],
                "nci_thesaurus_concept_id": "C140174",
                "name": "Stage IVA Prostate Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C140173"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IVB Prostate Carcinoma AJCC v8",
                    "Stage IVB Prostate Cancer AJCC v8",
                    "IVB"
                ],
                "nci_thesaurus_concept_id": "C140175",
                "name": "Stage IVB Prostate Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C140173"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Prostate Adenocarcinoma"
                ],
                "nci_thesaurus_concept_id": "C8945",
                "name": "Metastatic Prostatic Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8946",
                    "C4124",
                    "C2919"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Prostate Cancer Metastatic",
                    "Prostate Carcinoma Metastatic",
                    "Metastatic Prostate Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C8946",
                "name": "Metastatic Prostate Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4863",
                    "C146893"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Genital Disorders",
                    "Reproductive System Disease",
                    "Disorder of Reproductive System"
                ],
                "nci_thesaurus_concept_id": "C4875",
                "name": "Reproductive System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C156660"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Genitourinary System Cancer",
                    "Genitourinary Cancer",
                    "Malignant Genitourinary Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C156484",
                "name": "Malignant Genitourinary System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C156482"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Genitourinary System Malignant Neoplasm",
                    "Metastatic Malignant Genitourinary System Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C157774",
                "name": "Metastatic Genitourinary Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C156484",
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C167255",
                "name": "Refractory Prostate Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4863",
                    "C177149"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Prostate Disease"
                ],
                "nci_thesaurus_concept_id": "C26865",
                "name": "Prostate Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27019"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor_Morphology",
                    "Tumor Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C8511",
                "name": "Refractory Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Neoplasm of the Prostate",
                    "Malignant Tumor of the Prostate",
                    "Malignant Neoplasm of Prostate",
                    "Malignant Prostate Tumor",
                    "Malignant Tumor of Prostate"
                ],
                "nci_thesaurus_concept_id": "C7378",
                "name": "Malignant Prostate Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3343",
                    "C8561"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Urogenital Disease",
                    "Genitourinary Disorder"
                ],
                "nci_thesaurus_concept_id": "C156660",
                "name": "Genitourinary System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Epithelioma",
                    "Epithelioma, malignant",
                    "Epithelial Neoplasms, NOS"
                ],
                "nci_thesaurus_concept_id": "C3709",
                "name": "Epithelial Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C177149",
                "name": "Refractory Male Reproductive System Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C181196",
                    "C150534",
                    "C8511"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C181196",
                "name": "Male Reproductive System Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C164141",
                    "C8561"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor of the Male Reproductive System",
                    "Male Reproductive System Tumor",
                    "Tumor of Male Reproductive System",
                    "Neoplasm of Male Reproductive System",
                    "Neoplasm of the Male Reproductive System"
                ],
                "nci_thesaurus_concept_id": "C3054",
                "name": "Male Reproductive System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27019",
                    "C3674"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C150534",
                "name": "Refractory Malignant Male Reproductive System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8561",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Cancer of the Prostate",
                    "Other Prostate Carcinoma",
                    "Carcinoma of Prostate",
                    "Carcinoma of the Prostate",
                    "Prostate cancer, NOS",
                    "Cancer of Prostate",
                    "Prostate Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C4863",
                "name": "Prostate Cancer",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C181196",
                    "C7378"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Carcinoma, metastatic, NOS"
                ],
                "nci_thesaurus_concept_id": "C3482",
                "name": "Metastatic Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C36310"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Urogenital Carcinoma",
                    "Metastatic Genitourinary Cancer",
                    "Metastatic Genitourinary Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C146893",
                "name": "Metastatic Genitourinary System Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C164141",
                    "C3482",
                    "C157774"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Male Reproductive System Disease",
                    "Disorder of Male Reproductive System"
                ],
                "nci_thesaurus_concept_id": "C27019",
                "name": "Male Reproductive System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4875"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C164141",
                "name": "Genitourinary System Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C156484"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Tumor of the Male Reproductive System",
                    "Malignant Neoplasm of Male Reproductive System",
                    "Malignant Tumor of Male Reproductive System",
                    "Male reproductive system cancer, NOS",
                    "Malignant Male Reproductive System Tumor",
                    "Male reprod. system cancer, NOS",
                    "Malignant Neoplasm of the Male Reproductive System"
                ],
                "nci_thesaurus_concept_id": "C8561",
                "name": "Malignant Male Reproductive System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3054",
                    "C36076"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Epithelial Neoplasm",
                    "Epithelial tumor, malignant",
                    "Carcinoma",
                    "Carcinoma, NOS",
                    "Malignant Epithelioma",
                    "Epithelioma Malignant",
                    "CARCINOMA, MALIGNANT",
                    "Malignant Epithelial Tumor",
                    "Epithelial Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C2916",
                "name": "Other Carcinoma",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C9305",
                    "C3709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C36310",
                "name": "Secondary Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C4968"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Prostate Tumor",
                    "Tumor of the Prostate",
                    "Neoplasm of the Prostate",
                    "Neoplasm of Prostate",
                    "Tumor of Prostate"
                ],
                "nci_thesaurus_concept_id": "C3343",
                "name": "Prostate Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3054",
                    "C26865"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C36076",
                "name": "Malignant Reproductive System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C156484",
                    "C3674"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C156482",
                "name": "Genitourinary System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C156660",
                    "C3263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm of the Reproductive System",
                    "Reproductive Neoplasm",
                    "Reproductive System Tumor",
                    "Neoplasm of Reproductive System",
                    "Reproductive Tumor",
                    "Tumor of Reproductive System",
                    "Tumor of the Reproductive System"
                ],
                "nci_thesaurus_concept_id": "C3674",
                "name": "Reproductive System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4875",
                    "C156482"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Glandular Cell Epithelium Neoplasm",
                    "Glandular Cell Epithelial Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C7132",
                "name": "Glandular Cell Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Tumor Stage (Pathologic)",
                    "Prostate Carcinoma by AJCC v8 Stage"
                ],
                "nci_thesaurus_concept_id": "C140163",
                "name": "Prostate Cancer by AJCC v8 Stage",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4863"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "PRAD",
                    "Adenocarcinoma of Prostate",
                    "Adenocarcinoma of the Prostate"
                ],
                "nci_thesaurus_concept_id": "C2919",
                "name": "Prostate Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2852",
                    "C48596"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C9480",
                "name": "Invasive Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8505",
                    "C2916"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "invasive cancer",
                    "infiltrating cancer",
                    "Infiltrating Malignant Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C8505",
                "name": "Invasive Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Adenocarcinoma, NOS",
                    "ADENOCARCINOMA, MALIGNANT"
                ],
                "nci_thesaurus_concept_id": "C2852",
                "name": "Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C7132"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Infiltrating Prostate Carcinoma",
                    "Invasive Prostate Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C48596",
                "name": "Invasive Prostate Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4863",
                    "C9480"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Adenocarcinoma, metastatic, NOS"
                ],
                "nci_thesaurus_concept_id": "C4124",
                "name": "Metastatic Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3482",
                    "C2852"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "A206T-G01-001",
        "active_sites_count": 1,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug",
                            "Drug Substance",
                            "Pharmacological Substance",
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmaceutical Agent",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radiochemical",
                            "Radioactive Pharmaceutical",
                            "Radiopharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1446",
                        "name": "Radiopharmaceutical Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C150467",
                        "name": "Lutetium Lu-177 PSMA-R2",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C129819",
                            "C2124"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radio Conjugates"
                        ],
                        "nci_thesaurus_concept_id": "C2124",
                        "name": "Radioconjugate",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1446"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Cancer Drug",
                            "Antiproliferative Agents",
                            "Anti-Tumor Drugs",
                            "Antineoplastics",
                            "Anti-Tumor Agents",
                            "Anti-Cancer Agents",
                            "Tumor-Specific Treatment Agents",
                            "Antiproliferative Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Radiopharmaceutical",
                            "Anti-cancer Radiopharmaceutical"
                        ],
                        "nci_thesaurus_concept_id": "C129819",
                        "name": "Antineoplastic Radiopharmaceutical Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1446",
                            "C274"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 1",
                "description": "3.70 GBq (100 mCi) x 3 times",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 2",
                "description": "7.40 GBq (200 mCi) up to 4 times",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 3",
                "description": "11.1 GBq (300 mCi) up to 4 times",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 4",
                "description": "14.8 GBq (400 mCi) up to 4 times",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 5",
                "description": "18.5 GBq (500 mCi) up to 4 times",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase I: Dose Escalation Cohort 6",
                "description": "18.5 GBq (500 mCi) up to 3 times",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2018-00938",
        "why_study_stopped": "Recruitment for PROter A206T-G01-001 (NCT03490838) was halted in Phase I by sponsor decision.\r\n    Phase II expansion portion of the study was never initiated.",
        "brief_summary": "This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation\r\n      dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with\r\n      metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study\r\n      will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC,\r\n      and the Phase 2 portion will expand into approximately 60 patients documenting the\r\n      preliminary activity (anti-tumor response) of repeated treatments administered, continuing\r\n      safety assessments and collecting QoL data.",
        "brief_title": "177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer",
        "status_history": [
            {
                "status_date": "2022-06-02T00:00:00.000005",
                "status": "ADMINISTRATIVELY_COMPLETE"
            },
            {
                "status_date": "2021-10-20T00:00:00.000004",
                "status": "CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2019-02-07T01:03:12.582003",
                "status": "ACTIVE"
            },
            {
                "status_date": "2018-10-03T00:00:00.000002",
                "status": "TEMPORARILY_CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2018-06-07T02:02:59.611001",
                "status": "ACTIVE"
            },
            {
                "status_date": "2018-05-10T12:22:29.237",
                "status": "IN_REVIEW"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 96,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 8,
        "start_date": "2018-05-24",
        "record_verification_date": "2022-06-01",
        "ctep_id": null,
        "current_trial_status": "Administratively Complete",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": "PROter",
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Prostate"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2022-06-02",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]